About Haisco Pharmaceutical Group
Haisco Pharmaceutical Group is a publicly listed company based in Chengdu (China) founded in 2009. Pharmaceutical products are developed for various therapeutic areas. The company has 5,340 employees. Its website haisco.com draws about 39 thousand monthly visits. Haisco Pharmaceutical Group offers products and services including Anesthesia Drugs and Oncology Drugs. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is HaiSike Pharmaceutical Group Co., Ltd.
Company details
Haisco Pharmaceutical Group was established in 2009 in Chengdu, China, within the pharmaceuticals sector. Drug development is conducted for areas such as anesthetic analgesics, endocrine system treatments, and oncology. A pipeline of new candidates is advanced, while the portfolio includes products for the nervous system, cardiovascular conditions, digestive and liver diseases, and mens health. Operations emphasize research to support market introduction of therapies.
- Headquarters Chengdu, China
- Employees 5,340
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website haisco.com
- Social LinkedIn
- Legal Name Haisco Pharmaceutical Group Co. Ltd. Class A
- Annual Revenue$621.34 M (USD)17.82as on Dec 31, 2025
- Net Profit$37.08 M (USD)-34.36as on Dec 31, 2025
- EBITDA$65.58 M (USD)12.9as on Dec 31, 2025
- Employee Count5,340
Products & Services of Haisco Pharmaceutical Group
Haisco Pharmaceutical Group offers a comprehensive portfolio of products and services, including Anesthesia Drugs and Oncology Drugs.
Drugs for anesthesia and pain management are developed and supplied for medical use
Drugs related to tumors and antiemetics are researched and provided for treatment purposes
IPO & Listings of Haisco Pharmaceutical Group
Haisco Pharmaceutical Group is a publicly listed company on the SZSE with ticker symbol 002653 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jan 2012
- Listed onSZSE: 2653
- Listed entityHaisco Pharmaceutical Group Co. Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE100001BC7
- Share price58.08 CNY (-2.91% on the day) · 2026-10-14
- Market capitalisation67,956,987,405.00 CNY
- Price to earnings66.2
- EPS (diluted, trailing year)0.88 CNY
- Dividend yield1.33%
- Volume (last session)5,588,117
Financials of Haisco Pharmaceutical Group
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4.35B CNY | 259.6M CNY | 459.1M CNY |
| 2024 | 3.69B CNY | 395.5M CNY | 406.6M CNY |
| 2023 | 3.32B CNY | 295.1M CNY | 529.2M CNY |
| 2022 | 2.99B CNY | 277.1M CNY | 337.6M CNY |
| 2021 | 2.76B CNY | 345.1M CNY | 204.8M CNY |
Detailed financial statements for Haisco Pharmaceutical Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Haisco Pharmaceutical Group
The website of Haisco Pharmaceutical Group (haisco.com) receives about 38.8K visits a month and ranks #5,725,662 among all websites worldwide, #6,216 in Biotechnology and Pharmaceuticals.
- Monthly visits38.8K
▲ 1738.3% vs previous month
- Global rank#5,725,662
among all websites
- Category rank#6,216
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit3.6
- Average visit1 min 56 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Haisco Pharmaceutical Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
chinabiotoday.com | chinabiotoday.com | 100% | – | ||
| dxy.cn | 60% | 1.1M | #37,799 | View details | |
ifulibl.org | ifulibl.org | 33% | – | ||
qizhaishe.com | qizhaishe.com | 31% | – | ||
| chaojibiaoge.com | 31% | 23.7K | #1,280,472 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Haisco Pharmaceutical Group
Complete news archive for Haisco Pharmaceutical Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Haisco Pharmaceutical Group
Haisco Pharmaceutical Group was founded in 2009.
Haisco Pharmaceutical Group is headquartered in Chengdu, China. It is registered at Chengdu, Sichuan, China.
Haisco Pharmaceutical Group has 5,340 employees.
Annual revenue of Haisco Pharmaceutical Group is $621.34M as on Dec 31, 2025.
Haisco Pharmaceutical Group was established in 2009 in Chengdu, China, within the pharmaceuticals sector. Drug development is conducted for areas such as anesthetic analgesics, endocrine system treatments, and oncology. A pipeline of new candidates is advanced, while the portfolio includes products for the nervous system, cardiovascular conditions, digestive and liver diseases, and mens health. Operations emphasize research to support market introduction of therapies.
Haisco Pharmaceutical Group offers Anesthesia Drugs and Oncology Drugs.
Yes, Haisco Pharmaceutical Group is publicly traded on SZSE under the ticker symbol 002653.
Haisco Pharmaceutical Group operates through Haisike Pharmaceutical Group Co., Ltd.